Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, Sawai Group Holdings fair value estimate is JP¥12,020
- Current share price of JP¥6,320 suggests Sawai Group Holdings is potentially 47% undervalued
- Our fair value estimate is 66% higher than Sawai Group Holdings' analyst price target of JP¥7,230
Today we will run through one way of estimating the intrinsic value of Sawai Group Holdings Co., Ltd. (TSE:4887) by estimating the company's future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
View our latest analysis for Sawai Group Holdings
Crunching The Numbers
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (¥, Millions) | JP¥14.1b | JP¥10.7b | JP¥14.0b | JP¥15.6b | JP¥17.8b | JP¥19.4b | JP¥20.6b | JP¥21.5b | JP¥22.1b | JP¥22.6b |
Growth Rate Estimate Source | Analyst x5 | Analyst x5 | Analyst x4 | Analyst x4 | Analyst x3 | Est @ 8.63% | Est @ 6.12% | Est @ 4.36% | Est @ 3.13% | Est @ 2.27% |
Present Value (¥, Millions) Discounted @ 4.2% | JP¥13.5k | JP¥9.8k | JP¥12.4k | JP¥13.2k | JP¥14.5k | JP¥15.1k | JP¥15.4k | JP¥15.4k | JP¥15.2k | JP¥14.9k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = JP¥139b
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.3%. We discount the terminal cash flows to today's value at a cost of equity of 4.2%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = JP¥23b× (1 + 0.3%) ÷ (4.2%– 0.3%) = JP¥570b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= JP¥570b÷ ( 1 + 4.2%)10= JP¥376b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is JP¥515b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of JP¥6.3k, the company appears quite good value at a 47% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
The Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Sawai Group Holdings as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 4.2%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Sawai Group Holdings
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- Dividend is low compared to the top 25% of dividend payers in the Pharmaceuticals market.
- Annual revenue is forecast to grow faster than the Japanese market.
- Good value based on P/E ratio and estimated fair value.
- Paying a dividend but company has no free cash flows.
- Annual earnings are forecast to grow slower than the Japanese market.
Looking Ahead:
Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. What is the reason for the share price sitting below the intrinsic value? For Sawai Group Holdings, we've put together three additional items you should consider:
- Risks: For example, we've discovered 1 warning sign for Sawai Group Holdings that you should be aware of before investing here.
- Future Earnings: How does 4887's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Japanese stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4887
Sawai Group Holdings
Together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals.
Excellent balance sheet with proven track record and pays a dividend.